<DOC>
	<DOCNO>NCT00002183</DOCNO>
	<brief_summary>To assess safety tolerance multiple oral dos 141W94 alone , combination 1592U89 , combination Retrovir Epivir , administer patient HIV infection measure development clinical adverse experience laboratory test abnormality . To determine steady-state pharmacokinetics 141W94 alone combination 1592U89 multiple oral dosing . To obtain preliminary evidence antiretroviral activity 141W94 alone combination 1592U89 , antiretroviral effect combine Retrovir/Epivir antiretroviral effect 141W94 add Retrovir/Epivir 1592U89/Retrovir/Epivir .</brief_summary>
	<brief_title>A Phase I Trial Evaluate Safety , Pharmacokinetics Antiviral Activity 141W94 After Multiple Dosing Patients With HIV Infection</brief_title>
	<detailed_description>60 HIV-infected patient sequentially assign receive 1 5 dos 141W94 alone 141W94 plus 1592U89 . After patient complete 4 week assign regimen ( Phase A ) , patient receive Epivir Retrovir 8 month ( Phase B ) . Patients originally assign , Phase A , receive 141W94 1592U89 continue receive 1592U89 period . Upon termination Phase B , 141W94 add exist regimen Phase B ( Phase C ) . Phase C last 12 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Localized therapy intralesional injection Kaposi 's sarcoma . Patients must : HIV infection document license HIV antibody ELISA confirm : Western blot , positive HIV blood culture , positive HIV serum antigen second antibody test positive method ELISA . CD4+ count &gt; = 150 &lt; = 400 cells/mm3 within 2 week study entry . 1 . Anticipated need cytotoxic chemotherapeutic agent within 4 week prior entry . Alprazolam , carbamazepine , codeine , clarithromycin , dapsone , diazepam , diltiazem , erythromycin , estrogens , glucocorticoid , imipramine , itraconazole , ketoconazole , lidocaine , lovastatin , nifedipine , phenobarbital , phenytoin , quinidine , rifabutin , rifampin warfarin . The following medication use caution instance : terfenadine , astemizole , cisapride , triazolam midazolam . Anticipated need treatment radiation therapy within 4 week prior entry . 1 . Treatment cytotoxic chemotherapeutic agent within 4 week prior entry . Patients previously receive protease inhibitor . Antiretroviral therapy within 2 week prior enrollment . NOTE : Patients know intolerance either retrovir epivir eligible Phase B study . NOTE : Patients previous epivir ( 3TC ) experience eligible Regimen 6 study ( combination therapy 141W94 1592U89 ) . Treatment immunomodulating agent , include limited systemic corticosteroid , IL2 , alphaIFN , betaIFN , gammaIFN within 4 week prior entry . Treatment HIV immunotherapeutic vaccine within 3 month prior entry . Treatment radiation therapy within 4 week prior entry . Patients current alcohol illicit drug use , opinion principal investigator , may interfere patient ' ability comply dose schedule protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1997</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>VX 478</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>